Stemline Therapeutics Inc. (NASDAQ:STML) – Stock analysts at Roth Capital dropped their Q3 2016 earnings estimates for shares of Stemline Therapeutics in a research note issued on Tuesday. Roth Capital analyst J. Pantginis now expects that the firm will post earnings of ($0.56) per share for the quarter, down from their prior forecast of ($0.52). Roth Capital has a “Buy” rating and a $32.00 price objective on the stock. Roth Capital also issued estimates for Stemline Therapeutics’ Q4 2016 earnings at ($0.56) EPS and FY2016 earnings at ($2.04) EPS.

Other equities analysts have also issued research reports about the company. Jefferies Group reiterated a “buy” rating on shares of Stemline Therapeutics in a research report on Friday, August 5th. Zacks Investment Research raised Stemline Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research note on Wednesday, October 5th. Finally, Wedbush reissued an “outperform” rating and issued a $15.00 price objective on shares of Stemline Therapeutics in a research note on Tuesday, August 23rd. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $20.50.

Earnings History and Estimates for Stemline Therapeutics (NASDAQ:STML)

Stemline Therapeutics (NASDAQ:STML) opened at 12.25 on Friday. Stemline Therapeutics has a 12-month low of $3.88 and a 12-month high of $14.20. The firm has a 50-day moving average price of $11.66 and a 200-day moving average price of $8.43. The stock’s market cap is $218.36 million.

Several large investors have recently bought and sold shares of STML. Emerald Acquisition Ltd. purchased a new stake in Stemline Therapeutics during the second quarter worth $129,000. California State Teachers Retirement System increased its stake in Stemline Therapeutics by 6.1% in the second quarter. California State Teachers Retirement System now owns 35,349 shares of the biopharmaceutical company’s stock worth $239,000 after buying an additional 2,019 shares during the period. Carl Domino Inc increased its stake in Stemline Therapeutics by 12.9% in the second quarter. Carl Domino Inc now owns 26,305 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 3,000 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in Stemline Therapeutics during the first quarter worth $232,000. Finally, State Street Corp increased its stake in Stemline Therapeutics by 1.9% in the second quarter. State Street Corp now owns 220,768 shares of the biopharmaceutical company’s stock worth $1,493,000 after buying an additional 4,197 shares during the period. 52.60% of the stock is owned by institutional investors.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

5 Day Chart for NASDAQ:STML

Receive News & Stock Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related stocks with our FREE daily email newsletter.